Pfizer, a major player in the pharmaceutical industry, has recently shared more details about its weight loss drug pipeline. This comes as part of their efforts to compete in the growing market for weight loss medications, currently dominated by Novo Nordisk and Eli Lilly. These companies have found success with medications that mimic hormones to control blood sugar and suppress appetite, known as incretin drugs. Pfizer is now focusing on developing weight loss pills, which could help overcome supply constraints and appeal to patients who prefer not to take injections.

One of Pfizer's main candidates, danuglipron, is a pill that mimics the gut hormone GLP-1. Early trials showed promising results, with patients losing between 8% and 13% of their weight. However, a twice-daily version of the pill was dropped due to high side effects. The company is now testing different doses and expects to share more details in early 2025.

Additionally, Pfizer is working on other weight loss pills, including a once-daily GLP-1 pill and a pill that blocks the gut hormone GIP. These new drugs aim to offer better tolerability and efficacy. The company hopes to be the second to introduce an incretin weight loss pill, potentially capturing a decent market share.

Other pharmaceutical companies like Viking Therapeutics, Roche, and Amgen are also developing weight loss meds. The market for these drugs is expected to reach $105 billion by 2030, making it a highly competitive and lucrative area.

Pfizer Joins the Weight Loss Drug Race with Promising Pills

Actions